sipuleucel-T
Sign in to saveAlso known as apc8015, apc-8015, Provenge
Sipuleucel-T, sold under the brand name Provenge, developed by Dendreon Pharmaceuticals, LLC, is a cell-based cancer immunotherapy for prostate cancer (CaP). It is an autologous cellular immunotherapy.
Chemical data
Drug data · ChEMBL
- Max clinical phase
- Approved
- Molecule type
- Cell
- Indications
- metastatic prostate cancer, prostate adenocarcinoma, prostate cancer, neoplasm
via ChEMBL · EBI
Research
789 papers- Sipuleucel-T immunotherapy for castration-resistant prostate cancer.The New England journal of medicine · 2010
- Sipuleucel-T for the treatment of prostate cancer: novel insights and future directions.Future oncology (London, England) · 2018
- Sipuleucel-T: immunotherapy for advanced prostate cancer.Open access journal of urology · 2011
- Sipuleucel-T: in metastatic castration-resistant prostate cancer.Drugs · 2011
- Sipuleucel-T (Provenge®) for castration-resistant prostate cancer.BJU international · 2012
via PubMed
Wikidata facts
- Subclass of
- chemical compound
- Official website
- www.provenge.com
- Has use
- medication
Show 2 more facts
- NCI Thesaurus ID
- C1985
- subject has role
- immunostimulant
Sources (2)
via Wikidata · CC0
~5 min read
Encyclopedic overview
11 sectionsContents
- Medical uses
- Treatment method
- Side effects
- Society and culture
- Legal status
- Research
- Clinical trials
- Completed
- Ongoing
- References
- Further reading
Sipuleucel-T, sold under the brand name Provenge, developed by Dendreon Pharmaceuticals, LLC, is a cell-based cancer immunotherapy for prostate cancer (CaP). It is an autologous cellular immunotherapy.
== Medical uses == Sipuleucel-T is indicated for the treatment of metastatic, asymptomatic or minimally symptomatic, metastatic castrate-resistant hormone-refractory prostate cancer (HRPC). Other names for this stage are metastatic castrate-resistant (mCRPC) and androgen independent (AI) or (AIPC). This stage leads to mCRPC with lymph node involvement and distal (distant) tumors; this is the lethal stage of CaP. The prostate cancer staging designation is T4,N1,M1c.
Excerpted from Wikipedia’s “sipuleucel-T” article, available under the CC BY-SA 4.0 licence.